Silence Therapeutics PLC Purchase of ADS and PDMR Shareholding (8091V)
April 19 2021 - 01:00AM
UK Regulatory
TIDMSLN
RNS Number : 8091V
Silence Therapeutics PLC
19 April 2021
Purchase of American Depositary Shares and PDMR Dealings
19(th) April 2021
LONDON, Silence Therapeutics plc, AIM:SLN and Nasdaq: SLN
("Silence" or "the Company"), a leader in the discovery,
development and delivery of novel short interfering ribonucleic
acid (siRNA) therapeutics for the treatment of diseases with
significant unmet medical need, today announced that, on 16 April
2021 the following purchases of American Depositary Shares
("ADSs"), each representing three ordinary shares of 5 pence each
in the capital of the Company ("Ordinary Shares"), were made by
persons discharging managerial responsibilities at a purchase price
of $23.09 per ADS: 4,331 ADSs were purchased by Steven Romano,
Non-Executive Director of the Company, 4,331 ADSs were purchased by
Michael Davidson, MD, Non-Executive Director of the Company, 217
ADSs were purchased by Dave Lemus, Non-Executive Director of the
Company, 6,063 ADSs were purchased by Mark Rothera, Chief Executive
Officer and Executive Director of the Company and 8,662 ADSs were
purchased by Craig Tooman, Chief Financial Officer of the
Company.
The notifications below, made in accordance with the
requirements of the EU Market Abuse Regulation as it forms part of
UK law by virtue of the European Union (Withdrawal) Act 2018,
provide further detail.
Notification and public disclosure of transactions by persons
discharging managerial responsibilities and persons closely
associated with them
1. Details of the person discharging managerial responsibilities
(PDMR) / person closely associated
a) Name Steven Romano
--------------------------- -----------------------------------------
2. Reason for the notification
----------------------------------------------------------------------
a) Position / status Non-Executive Director
--------------------------- -----------------------------------------
b) Initial notification Initial notification
/ Amendment
--------------------------- -----------------------------------------
3. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
----------------------------------------------------------------------
a) Name Silence Therapeutics plc
--------------------------- -----------------------------------------
b) LEI 213800SSURRJBX85SQ91
--------------------------- -----------------------------------------
4 Details of the transaction(s): section to be repeated for
(i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions
have been conducted
----------------------------------------------------------------------
a) Description of American Depositary Shares (ADSs) , each
the financial instrument, of which represents three (3) Ordinary
type of instrument Shares of 5 pence each in the capital
of Silence Therapeutics plc
Identification ISIN for Silence Therapeutics plc ADSs:
code US82686Q1013
--------------------------- -----------------------------------------
b) Nature of the transaction Purchase of ADSs in Silence Therapeutics
plc
--------------------------- -----------------------------------------
c) Price(s) and volume(s) Price Volume
$23.09 4,331
-------
--------------------------- -----------------------------------------
d) Aggregated information
- Aggregated volume 4,331 ADSs
- Price $100,002.79
--------------------------- -----------------------------------------
e) Date of the transaction 16 April 2021
--------------------------- -----------------------------------------
f) Place of the transaction Outside a trading venue
--------------------------- -----------------------------------------
1. Details of the person discharging managerial responsibilities
(PDMR) / person closely associated
a) Name Michael Davidson
--------------------------- -----------------------------------------
2. Reason for the notification
----------------------------------------------------------------------
a) Position / status Non-Executive Director
--------------------------- -----------------------------------------
b) Initial notification Initial notification
/ Amendment
--------------------------- -----------------------------------------
3. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
----------------------------------------------------------------------
a) Name Silence Therapeutics plc
--------------------------- -----------------------------------------
b) LEI 213800SSURRJBX85SQ91
--------------------------- -----------------------------------------
4 Details of the transaction(s): section to be repeated for
(i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions
have been conducted
----------------------------------------------------------------------
a) Description of American Depositary Shares (ADSs) , each
the financial instrument, of which represents three (3) Ordinary
type of instrument Shares of 5 pence each in the capital
of Silence Therapeutics plc
Identification
code ISIN for Silence Therapeutics plc ADSs:
US82686Q1013
--------------------------- -----------------------------------------
b) Nature of the transaction Purchase of ADSs in Silence Therapeutics
plc
--------------------------- -----------------------------------------
c) Price(s) and volume(s) Price Volume
$23.09 4,331
-------
--------------------------- -----------------------------------------
d) Aggregated information
- Aggregated volume 4,331 ADSs
- Price $100,002.79
--------------------------- -----------------------------------------
e) Date of the transaction 16 April 2021
--------------------------- -----------------------------------------
f) Place of the transaction Outside a trading venue
--------------------------- -----------------------------------------
1. Details of the person discharging managerial responsibilities
(PDMR) / person closely associated
a) Name Dave Lemus
--------------------------- -----------------------------------------
2. Reason for the notification
----------------------------------------------------------------------
a) Position / status Non-Executive Director
--------------------------- -----------------------------------------
b) Initial notification Initial notification
/ Amendment
--------------------------- -----------------------------------------
3. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
----------------------------------------------------------------------
a) Name Silence Therapeutics plc
--------------------------- -----------------------------------------
b) LEI 213800SSURRJBX85SQ91
--------------------------- -----------------------------------------
4 Details of the transaction(s): section to be repeated for
(i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions
have been conducted
----------------------------------------------------------------------
a) Description of American Depositary Shares (ADSs), each
the financial instrument, of which represents three (3) Ordinary
type of instrument Shares of 5 pence each in the capital
of Silence Therapeutics plc
Identification
code ISIN for Silence Therapeutics plc ADSs:
US82686Q1013
--------------------------- -----------------------------------------
b) Nature of the transaction Purchase of ADSs in Silence Therapeutics
plc
--------------------------- -----------------------------------------
c) Price(s) and volume(s) Price Volume
$23.09 217
-------
--------------------------- -----------------------------------------
d) Aggregated information
- Aggregated volume 217 ADSs
- Price $5,010.53
--------------------------- -----------------------------------------
e) Date of the transaction 16 April 2021
--------------------------- -----------------------------------------
f) Place of the transaction Outside a trading venue
--------------------------- -----------------------------------------
1. Details of the person discharging managerial responsibilities
(PDMR) / person closely associated
a) Name Mark Rothera
--------------------------- -----------------------------------------
2. Reason for the notification
----------------------------------------------------------------------
a) Position / status Chief Executive Officer and Executive
Director
--------------------------- -----------------------------------------
b) Initial notification Initial notification
/ Amendment
--------------------------- -----------------------------------------
3. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
----------------------------------------------------------------------
a) Name Silence Therapeutics plc
--------------------------- -----------------------------------------
b) LEI 213800SSURRJBX85SQ91
--------------------------- -----------------------------------------
4 Details of the transaction(s): section to be repeated for
(i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions
have been conducted
----------------------------------------------------------------------
a) Description of American Depositary Shares (ADSs) , each
the financial instrument, of which represents three (3) Ordinary
type of instrument Shares of 5 pence each in the capital
of Silence Therapeutics plc
Identification
code ISIN for Silence Therapeutics plc ADSs:
US82686Q1013
--------------------------- -----------------------------------------
b) Nature of the transaction Purchase of ADSs in Silence Therapeutics
plc
--------------------------- -----------------------------------------
c) Price(s) and volume(s) Price Volume
$23.09 6,063
-------
--------------------------- -----------------------------------------
d) Aggregated information
- Aggregated volume 6,063 ADSs
- Price $139,994.67
--------------------------- -----------------------------------------
e) Date of the transaction 16 April 2021
--------------------------- -----------------------------------------
f) Place of the transaction Outside a trading venue
--------------------------- -----------------------------------------
1. Details of the person discharging managerial responsibilities
(PDMR) / person closely associated
a) Name Craig Tooman
--------------------------- -----------------------------------------
2. Reason for the notification
----------------------------------------------------------------------
a) Position / status Chief Financial Officer
--------------------------- -----------------------------------------
b) Initial notification Initial notification
/ Amendment
--------------------------- -----------------------------------------
3. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
----------------------------------------------------------------------
a) Name Silence Therapeutics plc
--------------------------- -----------------------------------------
b) LEI 213800SSURRJBX85SQ91
--------------------------- -----------------------------------------
4 Details of the transaction(s): section to be repeated for
(i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions
have been conducted
----------------------------------------------------------------------
a) Description of American Depositary Shares (ADSs) , each
the financial instrument, of which represents three (3) Ordinary
type of instrument Shares of 5 pence each in the capital
of Silence Therapeutics plc
Identification
code ISIN for Silence Therapeutics plc ADSs:
US82686Q1013
--------------------------- -----------------------------------------
b) Nature of the transaction Purchase of ADSs in Silence Therapeutics
plc
--------------------------- -----------------------------------------
c) Price(s) and volume(s) Price Volume
$23.09 8,662
-------
--------------------------- -----------------------------------------
d) Aggregated information
- Aggregated volume 8,662 ADSs
- Price $200,005.58
--------------------------- -----------------------------------------
e) Date of the transaction 16 April 2021
--------------------------- -----------------------------------------
f) Place of the transaction Outside a trading venue
--------------------------- -----------------------------------------
Enquiries:
Silence Therapeutics plc Tel: +1 (646) 637-3208
Gem Hopkins, Head of IR & Corporate Communications
Investec Bank plc (Nominated Adviser and Tel: +44 (0) 20
Broker) 7597 5970
Daniel Adams/Gary Clarence
European PR Tel: +44 (0) 20
Consilium Strategic Communications 3709 5700
Mary-Jane Elliott/Chris Welsh/Angela Gray
silencetherapeutics@consilium-comms.com
About Silence Therapeutics plc
Silence Therapeutics is developing a new generation of medicines
by harnessing the body's natural mechanism of RNA interference, or
RNAi, to inhibit the expression of specific target genes thought to
play a role in the pathology of diseases with significant unmet
medical need. Silence's proprietary mRNAi GOLD(TM) platform can be
used to create siRNAs that precisely target and silence
disease-associated genes in the liver, which represents a
substantial opportunity. Silence's wholly owned product candidates
include SLN360 designed to address the high and prevalent unmet
medical need in reducing cardiovascular risk in people born with
high levels of lipoprotein(a) and SLN124 designed to address iron
loading anemias. Silence also maintains ongoing research and
development collaborations with AstraZeneca, Mallinckrodt
Pharmaceuticals, and Takeda, among others. For more information,
please visit https://www.silence-therapeutics.com/.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
DSHFZGMDGRKGMZZ
(END) Dow Jones Newswires
April 19, 2021 02:00 ET (06:00 GMT)
Silence Therapeutics (LSE:SLN)
Historical Stock Chart
From Feb 2024 to Mar 2024
Silence Therapeutics (LSE:SLN)
Historical Stock Chart
From Mar 2023 to Mar 2024